Home Capital Broker's Calls

DBS ups Delfi’s TP to $1.07 as it sees 'worst quarter' as over

Chloe Lim
Chloe Lim11/23/2021 03:49 PM GMT+08  • 3 min read
DBS ups Delfi’s TP to $1.07 as it sees 'worst quarter' as over
DBS Group Research analyst Chung Wei Le keeps “buy” on Delfi Limited., with an increased target price to $1.07.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

DBS Group Research analyst Chung Wei Le has kept “buy” on Delfi Limited., with an increased target price to $1.07 from $1.06.

The higher target price comes despite Delfi’s EBITDA for the 3QFY2021 ended September standing slightly below Chung’s expectations.

“Unfortunately, the rapid rise in Covid-19 cases in Indonesia and its regional markets in 3QFY2021 impacted sales and consequently margins due to lower economies of scale,” says Chung. As a result, EBITDA margins increased 1 percentage point (ppt) y-o-y to 7.3% from 6.3% on higher gross profit margins and tighter control on operating expenses.

On a sequential basis, sales had declined 4.5% yo-y due to the rise in Covid-19 cases in its key operating markets (Indonesia, Malaysia, and the Philippines) in 3QFY2021, weakening consumer sentiment, according to Chung.

In Indonesia, this also coincided with a seasonally low quarter post Lebaran. Delfi’s 3Q2021 revenue nevertheless increased 4.1% y-o-y to US$87.0 million ($118.6 million).

Despite this, Chung deems Delfi as being an undervalued consumer stock at an attractive valuation of 12.5 times FY2022 price-to-earnings (P/E). This, says Chung, is -1.8 standard deviation (s.d.) of Delfi’s four-year historical mean and is at a 38% discount to its Indonesian-focused peer-average of 20.1 times.

See also: DBS ups Sea Limited's TP to US$103 as it sees a turnaround in its e-commerce and fintech segments

“It is also positioned for recovery from FY2021-2023F, with an earnings compound annual growth rate (CAGR) of 25%,” writes Chung.

See: Delfi positioning for growth beyond the pandemic: CGS-CIMB

Chung considers Covid-19 as a main factor for Delfi’s previously tumultuous quarters. “As Covid-19 cases in its key operating regions begin to subside, vaccination rates rise, and countries learn to manage the Covid-19 pandemic better, we believe that we are past the worst quarter, which was 3QFY2020,” says the analyst.

See also: DBS cuts Yanlord target price from $1.43 to $1.06

Delfi has also recently redesigned its SilverQueen brand to target the younger individuals in Indonesia. Delfi has launched two new healthier products as well as refreshed products under SilverQueen, according to Chung. “These efforts are to target the Gen-Z and Millennials in Indonesia, and we believe this initiative allows Delfi to capitalise on Indonesia’s growing millennial middle class,” he says.

A possible worsening of the Covid-19 pandemic in Indonesia and regional markets could be a potential risk however, the analyst noted, although Chung asserts that Delfi is “onward to brighter quarters.”

For more stories about where the money flows, click here for our Capital section

Chung is expecting revenue to grow 8% y-o-y in FY2022, and is projecting earnings to grow 33% on the back of an improvement in margins due to economies of scale. “As Covid-19 cases in these regions begin to subside and as Indonesia’s consumer confidence index recovers, we believe that Delfi’s sales and earnings will gradually recover in the next few quarters,” he says.

At 3:11pm, shares in Delfi are up 2.5 cents or 3.23% higher at 80 cents.

Photo: Delfi

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.